{"id":8589,"date":"2026-08-11T22:47:06","date_gmt":"2026-08-11T22:47:06","guid":{"rendered":"https:\/\/roidshopcanada.com\/?page_id=8589"},"modified":"2026-08-11T22:47:06","modified_gmt":"2026-08-11T22:47:06","slug":"retatrutide-10mg-vs-other-research-peptides","status":"publish","type":"page","link":"https:\/\/roidshopcanada.com\/en\/retatrutide-10mg-vs-other-research-peptides\/","title":{"rendered":"Retatrutide 10mg vs Other Research Peptides"},"content":{"rendered":"
\n
\n

Retatrutide 10mg vs Other Research Peptides: Comparison Guide | roidshopcanada.com<\/h1>\n<\/div>\n
\n

How does Retatrutide 10mg<\/strong> compare to other research peptides like Semaglutide and Tirzepatide? Here\u2019s a quick overview for Canadian researchers:<\/p>\n<\/div>\n

\n
\n<\/div>\n\n\n\n\n\n\n\n
Peptide<\/th>\nPrimary Targets<\/th>\nWeight Loss Efficacy<\/th>\nGlycemic Control<\/th>\nMechanism<\/th>\nResearch Status<\/th>\n<\/tr>\n<\/thead>\n
Retatrutide<\/strong><\/td>\nGIP, GLP-1, Glucagon<\/td>\nExcellent<\/td>\nYes<\/td>\nTriple agonist<\/td>\nPhase III (2024)<\/td>\n<\/tr>\n
Semaglutide<\/td>\nGLP-1<\/td>\nVery Good<\/td>\nYes<\/td>\nSingle agonist<\/td>\nApproved\/Clinical<\/td>\n<\/tr>\n
Tirzepatide<\/td>\nGIP + GLP-1<\/td>\nExcellent<\/td>\nYes<\/td>\nDual agonist<\/td>\nApproved\/Clinical<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Retatrutide<\/strong> stands out as the only true triple agonist, with studies indicating potentially superior weight loss and metabolic improvements. However, it is still under investigation, while Semaglutide and Tirzepatide are already approved for clinical use.<\/p>\n<\/div>\n

\n
\n<\/div>\n
\n

Related Pages<\/h2>\n<\/div>\n